Impact of Emergency Department Probiotic Treatment of Pediatric Gastroenteritis (PROBIOTIC)

← Back to all studies

Impact of Emergency Department Probiotic Treatment of Pediatric Gastroenteritis (PROBIOTIC)

Health Condition: Gastroenteritis
Health Impact Domain: Safety of care, Effectiveness of care, Readmissions, Patient experience, Timeliness of care, Cost savings, Decreased incidence/length of hospitalization, Creation of decision tool, Equity lens

Summary

Acute gastroenteritis (AGE) is a leading cause of malnutrition and death worldwide and affects millions of children in the US each year. Most AGE is viral in origin, and apart from care focused on rehydration and nausea, there are no therapies to reduce the severity of illness. The overall objective of this randomized, placebo-controlled, double-blind, multi-center study is to determine the efficacy and side effect profile of the probiotic, Lactobacillus rhamnosus GG (LGG), in children aged 3 to 48 months presenting to the ED with AGE. Patients were randomized to receive either LGG or placebo twice a day for 5 days, for a total of 10 doses. Nine-hundred and seventy-one children were enrolled in 10 PECARN sites over 4 years. Enrollment completed in Summer 2017. Analysis is in progress. This project is funded by the NICHD.

Key Publications

Related Media

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of the Emergency Medical Services for Children Data Center award totaling $3,200,000 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov.